治疗性肝素与预防性肝素对住院中度COVID-19患者死亡、机械通气或ICU入住的有效性:RAPID随机临床试验
RAPID研究为随机、适应性、开放标签临床试验,纳入巴西、加拿大、爱尔兰、沙特阿拉伯、阿联酋和美国28家医院465例住院病房的中度COVID-19且D-二聚体升高的成人患者,随机分为治疗性肝素组(n=228)和预防性肝素组(n=237)。主要复合终点(死亡、有创/无创机械通气或ICU入住)28天发生率治疗组16.2% vs 预防组21.9%(OR 0.69,95%CI 0.43-1.10;P=0.12),差异无统计学意义。28天死亡治疗组1.8% vs 预防组7.6%(OR 0.22,95%CI 0.07-0.65;P=0.006),治疗性肝素显著降低死亡几率。大出血发生率两组均低(0.9% vs 1.7%),差异无统计学意义。
要点
- 住院病房中度COVID-19且D-二聚体升高的成人患者,治疗性肝素组28天死亡1.8%(4/228) vs 预防性肝素组7.6%(18/237),OR 0.22(95%CI 0.07-0.65;P=0.006)。
- 主要复合终点(死亡、有创或无创机械通气、ICU入住)治疗组16.2% vs 预防组21.9%,OR 0.69(95%CI 0.43-1.10;P=0.12),未达统计学显著。
- 全因死亡或任何机械通气的复合终点治疗组10.1% vs 预防组16.0%,OR 0.59(95%CI 0.34-1.02;P=0.06)。
- 大出血治疗组0.9%(2/228) vs 预防组1.7%(4/237),OR 0.52(95%CI 0.09-2.85;P=0.69),本试验中治疗性肝素大出血风险低。
- 静脉血栓栓塞治疗组0.9%(2/228) vs 预防组2.5%(6/237),OR 0.34(95%CI 0.07-1.71;P=0.19)。
适用人群与场景
- 纳入:住院病房(非ICU)的中度COVID-19成人患者,且D-二聚体水平升高;年龄均值60岁,男性56.8%,BMI均值30.3 kg/m2。
- 排除:原文未提及具体排除标准。
- 场景:住院病房,非急诊抢救室或ICU;病情阶段为中度COVID-19住院期。
诊断标准与关键阈值
- 纳入条件:成人、COVID-19住院病房患者、D-二聚体水平升高(原文未给出具体界值)。
- 主要终点评估至28天:死亡、有创机械通气、无创机械通气或ICU入住的复合终点。
处置流程与药物剂量
- 治疗性肝素组:给予治疗剂量肝素(低分子量肝素或普通肝素),持续至出院、第28天或死亡;原文未给出具体剂量、单位、给药途径和频次。
- 预防性肝素组:给予预防剂量肝素(低分子量肝素或普通肝素),持续至出院、第28天或死亡;原文未给出具体剂量、单位、给药途径和频次。
- 两组均未提及目标值(如抗Xa因子水平或APTT目标)。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:随机、适应性、开放标签临床试验;28家医院(巴西、加拿大、爱尔兰、沙特阿拉伯、阿联酋、美国);样本量465例(治疗性肝素228例,预防性肝素237例)。
- 主要终点:28天复合终点(死亡、有创机械通气、无创机械通气或ICU入住)治疗组16.2%(37/228) vs 预防组21.9%(52/237),OR 0.69(95%CI 0.43-1.10;P=0.12)。
- 关键次要终点:28天死亡治疗组1.8%(4/228) vs 预防组7.6%(18/237),OR 0.22(95%CI 0.07-0.65;P=0.006);全因死亡或任何机械通气复合终点10.1%(23/228) vs 16.0%(38/237),OR 0.59(95%CI 0.34-1.02;P=0.06);静脉血栓栓塞0.9%(2/228) vs 2.5%(6/237),OR 0.34(95%CI 0.07-1.71;P=0.19
- 安全性:大出血治疗组0.9%(2/228) vs 预防组1.7%(4/237),OR 0.52(95%CI 0.09-2.85;P=0.69)。
证据类型、等级与局限
- 证据类型:随机对照试验(RCT),适应性、开放标签设计。
- 证据等级或推荐强度:原文未提及。
- 局限:开放标签设计;主要终点未达统计学显著;样本量465例;事件数较少(死亡4 vs 18,大出血2 vs 4);原文未报告盲法对干预分配的影响。
对床旁实践的改变
- 对于住院病房中度COVID-19且D-二聚体升高的成人患者,治疗性肝素未显著降低死亡、机械通气或ICU入住的复合终点,但28天死亡几率显著降低,大出血风险低;该结果不适用于ICU患者或非住院人群。
- 原文未给出治疗性肝素的具体剂量方案,临床使用需参照所在机构方案;不能将本试验方案剂量推为通用推荐。
- 主要终点未达统计学显著,死亡获益为次要终点且事件数少,需谨慎解读,不能据此对所有中度COVID-19患者常规使用治疗性肝素。
指南或共识出处
- 原文未提及指南或共识名称;试验注册号ClinicalTrials.gov NCT04362085。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effects of therapeutic heparin compared with prophylactic heparin among moderately ill patients with covid-19 admitted to hospital wards.
DESIGN: Randomised controlled, adaptive, open label clinical trial.
SETTING: 28 hospitals in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and US.
PARTICIPANTS: 465 adults admitted to hospital wards with covid-19 and increased D-dimer levels were recruited between 29 May 2020 and 12 April 2021 and were randomly assigned to therapeutic dose heparin (n=228) or prophylactic dose heparin (n=237).
INTERVENTIONS: Therapeutic dose or prophylactic dose heparin (low molecular weight or unfractionated heparin), to be continued until hospital discharge, day 28, or death.
MAIN OUTCOME MEASURES: The primary outcome was a composite of death, invasive mechanical ventilation, non-invasive mechanical ventilation, or admission to an intensive care unit, assessed up to 28 days. The secondary outcomes included all cause death, the composite of all cause death or any mechanical ventilation, and venous thromboembolism. Safety outcomes included major bleeding. Outcomes were blindly adjudicated.
RESULTS: The mean age of participants was 60 years; 264 (56.8%) were men and the mean body mass index was 30.3 kg/m2. At 28 days, the primary composite outcome had occurred in 37/228 patients (16.2%) assigned to therapeutic heparin and 52/237 (21.9%) assigned to prophylactic heparin (odds ratio 0.69, 95% confidence interval 0.43 to 1.10; P=0.12). Deaths occurred in four patients (1.8%) assigned to therapeutic heparin and 18 patients (7.6%) assigned to prophylactic heparin (0.22, 0.07 to 0.65; P=0.006). The composite of all cause death or any mechanical ventilation occurred in 23 patients (10.1%) assigned to therapeutic heparin and 38 (16.0%) assigned to prophylactic heparin (0.59, 0.34 to 1.02; P=0.06). Venous thromboembolism occurred in two patients (0.9%) assigned to therapeutic heparin and six (2.5%) assigned to prophylactic heparin (0.34, 0.07 to 1.71; P=0.19). Major bleeding occurred in two patients (0.9%) assigned to therapeutic heparin and four (1.7%) assigned to prophylactic heparin (0.52, 0.09 to 2.85; P=0.69).
CONCLUSIONS: In moderately ill patients with covid-19 and increased D-dimer levels admitted to hospital wards, therapeutic heparin was not significantly associated with a reduction in the primary outcome but the odds of death at 28 days was decreased. The risk of major bleeding appeared low in this trial.
TRIAL REGISTRATION: ClinicalTrials.gov NCT04362085.
参考来源
- Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021. PMID: 34649864. doi:10.1136/bmj.n2400
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。